Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage
- PMID: 29439331
- PMCID: PMC6007886
- DOI: 10.3233/JAD-170602
Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage
Abstract
Inflammatory markers have been shown to predict neurocognitive outcomes in aging adults; however, the degree to which peripheral markers mirror the central nervous system remains unknown. We investigated the association between plasma and cerebrospinal fluid (CSF) markers of inflammation, and explored whether these markers independently predict CSF indicators of Alzheimer's disease (AD) pathology or neuronal damage. Plasma and CSF samples were analyzed for inflammatory markers in a cohort of asymptomatic older adults (n = 173). CSF samples were analyzed for markers of AD pathology (Aβ42, phosphorylated tau [p-tau], sAβPPβ) or neuronal damage (total tau; neurofilament light chain) (n = 147). Separate linear models for each analyte were conducted with CSF and plasma levels entered simultaneously as predictors and markers of AD pathology or neuronal damage as outcome measures. Strong associations were noted between CSF and plasma MIP-1β levels, and modest associations were observed for remaining analytes. With respect to AD pathology, higher levels of plasma and CSF IL-8, CSF MIP-1β, and CSF IP-10 were associated with higher levels of p-tau. Higher levels of CSF IL-8 were associated with higher levels of CSF Aβ42. Higher CSF sAβPPβ levels were associated with higher plasma markers only (IL-8; MCP-1). In terms of neuronal injury, higher levels of plasma and CSF IL-8, CSF IP-10, and CSF MIP-1β were associated with higher levels of CSF total tau. Exploratory analyses indicated that CSF Aβ42 modifies the relationship between plasma inflammatory levels and CSF tau levels. Results suggest that both plasma and CSF inflammatory markers independently relay integral information about AD pathology and neuronal damage.
Keywords: Aging; Alzheimer’s disease; biomarkers; neuroinflammation; preclinical AD; systemic inflammation.
Conflict of interest statement
The authors have no other disclosures or conflicts of interest.
Figures
Similar articles
-
Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.J Alzheimers Dis. 2016;50(3):873-86. doi: 10.3233/JAD-150897. J Alzheimers Dis. 2016. PMID: 26836182 Free PMC article.
-
Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.Brain Behav Immun. 2017 May;62:203-211. doi: 10.1016/j.bbi.2017.01.020. Epub 2017 Feb 1. Brain Behav Immun. 2017. PMID: 28161476
-
Glial activation and inflammation along the Alzheimer's disease continuum.J Neuroinflammation. 2019 Feb 21;16(1):46. doi: 10.1186/s12974-019-1399-2. J Neuroinflammation. 2019. PMID: 30791945 Free PMC article.
-
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8. Lancet Neurol. 2016. PMID: 27068280 Review.
-
Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.Mol Med Rep. 2016 Oct;14(4):3184-98. doi: 10.3892/mmr.2016.5618. Epub 2016 Aug 9. Mol Med Rep. 2016. PMID: 27511317 Free PMC article. Review.
Cited by
-
Is blood pTau a reliable indicator of the CSF status? A narrative review.Neurol Sci. 2023 Dec 22. doi: 10.1007/s10072-023-07258-x. Online ahead of print. Neurol Sci. 2023. PMID: 38129590 Review.
-
CSF metabolites associated with biomarkers of Alzheimer's disease pathology.Front Aging Neurosci. 2023 Aug 30;15:1214932. doi: 10.3389/fnagi.2023.1214932. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37719875 Free PMC article.
-
Circadian disruption and psychostimulants dysregulates plasma acute-phase proteins and circulating cell-free mitochondrial DNA.Brain Behav Immun Health. 2023 Jun 27;31:100659. doi: 10.1016/j.bbih.2023.100659. eCollection 2023 Aug. Brain Behav Immun Health. 2023. PMID: 37455861 Free PMC article.
-
Stealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511: Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer's Disease Mice.Int J Mol Sci. 2023 Jul 2;24(13):11013. doi: 10.3390/ijms241311013. Int J Mol Sci. 2023. PMID: 37446191 Free PMC article.
-
Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease.Int J Mol Sci. 2023 Jun 23;24(13):10523. doi: 10.3390/ijms241310523. Int J Mol Sci. 2023. PMID: 37445700 Free PMC article.
References
-
- Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358–372. - PubMed
-
- Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3:169–176. - PubMed
-
- Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005–1015. - PubMed
-
- Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci. 2008;1:30–41. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
